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Abstract
Background: Adipose tissue inflammation and dysregulated adipokine secretion are implicated in obesity-related insulin
resistance and type 2 diabetes. We evaluated the use of serum adiponectin, an anti-inflammatory adipokine, and several
proinflammatory adipokines, as biomarkers of diabetes risk and whether they add to traditional risk factors in diabetes
prediction.
Methods: We studied 1300 non-diabetic subjects from the prospective Hong Kong Cardiovascular Risk Factor Prevalence
Study (CRISPS). Serum adiponectin, tumor necrosis factor-alpha receptor 2 (TNF-a R2), interleukin-6 (IL-6), adipocyte–fatty
acid binding protein (A-FABP) and high-sensitivity C-reactive protein (hsCRP) were measured in baseline samples.
Results: Seventy-six participants developed diabetes over 5.3 years (median). All five biomarkers significantly improved the
log-likelihood of diabetes in a clinical diabetes prediction (CDP) model including age, sex, family history of diabetes,
smoking, physical activity, hypertension, waist circumference, fasting glucose and dyslipidaemia. In ROC curve analysis,
‘‘adiponectin + TNF-a R2’’ improved the area under ROC curve (AUC) of the CDP model from 0.802 to 0.830 (P = 0.03),
rendering its performance comparable to the ‘‘CDP + 2-hour post-OGTT glucose’’ model (AUC = 0.852, P = 0.30). A
biomarker risk score, derived from the number of biomarkers predictive of diabetes (low adiponectin, high TNF-a R2), had
similar performance when added to the CDP model (AUC = 0.829 [95% CI: 0.808–0.849]).
Conclusions: The combined use of serum adiponectin and TNF-a R2 as biomarkers provided added value over traditional
risk factors for diabetes prediction in Chinese and could be considered as an alternative to the OGTT.
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Introduction
Diabetes mellitus is an increasing global health problem. In a
recent study [1], the prevalence of diabetes in the Chinese
population in 2008 had increased to 9.7% among adults aged 20
years or older. Another 12.9% of the subjects in this study had
impaired glucose tolerance (IGT), known to be associated with a
highly elevated risk of diabetes development among various
populations including Hong Kong Chinese [2]. Without appro-
priate public health measures, it is anticipated that the increase in
diabetes prevalence in China will reach epidemic dimensions in
the near future. On a brighter note, it has been shown in long-
term prospective studies that lifestyle interventions can delay or
even prevent the onset of type 2 diabetes in high risk individuals
including subjects with IGT [3,4,5]. To identify the presence of
IGT, however, it is necessary to perform an oral glucose tolerance
test (OGTT) which is cumbersome and not consistently repro-
ducible. From a public health point of view, it would be very
helpful if alternative, more easily assessed biomarkers with high
predictive value for diabetes development can be identified.
Adipose tissue inflammation and dysregulated adipokine secre-
tion have been implicated in obesity-related insulin resistance and
type 2 diabetes [6,7]. High levels of the pro-inflammatory
biomarkers, such as interleukin-6 (IL-6), tumor necrosis factor-
alpha (TNF-a) or its soluble receptor tumor necrosis factor-alpha
receptor 2 (TNF-a R2), and C-reactive protein (CRP), are found
in obese individuals. In Chinese, high level of high sensitive C-
reactive protein (hsCRP) has been shown to independently predict
the deterioration of glycaemia [8]. In addition, IL-6 and TNF-a,
the upstream cytokines of C-reactive protein in the inflammatory
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cascades, have also been linked with an increased risk of type 2
diabetes in a previous report [9], although other studies have
shown inconsistent results [10,11,12]. Our group has previously
demonstrated that a high baseline level of adipocyte fatty acid
binding protein (A-FABP), a pro-inflammatory adipokine, is also
predictive of type 2 diabetes in a Chinese cohort [13]. Among the
various biomarkers, adiponectin, an anti-inflammatory, insulin-
sensitizing adipokine with reduced expression in obesity, has been
consistently linked with protection from type 2 diabetes
[10,11,12,14]. We have demonstrated, in a previous nested case-
control study, that hypoadiponectinaemia could predict persistent
hyperglycaemia in Chinese [14]. In this 5-year prospective study of
a population-based Chinese cohort, we examined the association
of the above obesity-related biomarkers with diabetes development
in the Chinese population and investigated if any of these
biomarkers have the potential to replace the OGTT for risk
prediction.
Methods
Ethics
The study was approved by the ethics committee of the Faculty
of Medicine, University of Hong Kong. All subjects gave written
informed consent.
Participants
The Hong Kong Cardiovascular Risk Factor Prevalence Study
(CRISPS) is a population-based, long-term follow-up study on the
prevalence of cardiovascular risk factors in Hong Kong.
[2,14,15,16] In 1995–1996 (CRISPS1), 2,895 unrelated Chinese
subjects were selected randomly by their telephone numbers to
undergo a comprehensive assessment, including a 75 g OGTT in
all subjects not on antidiabetic medications. Subjects were
contacted for reassessment in 2000–2004 (CRISPS2) and in
2005–2008 (CRISPS3). The current study included only the non-
diabetic subjects identified in CRISPS2 (baseline for this study), as
defined by the World Health Organization 1998 criteria [17].
1300 subjects who attended both CRISPS2 (baseline visit) and
CRISPS3 (follow-up visit) and had complete baseline anthropo-
metric and biochemical data were included for analysis. Subjects
who had FG $7 mmol/L or 2-hG $11.1 mmol/L [17] at
CRISPS3 or had been diagnosed to have diabetes between
CRISPS2 and CRISPS3 were considered as incident cases of type
2 diabetes. At each attendance, medical histories were reviewed in
detail. Anthropometric and biochemical parameters were mea-
sured as described previously [2,14,15,16]. The presence of
hypertension was defined as blood pressure $130/85 mmHg or
receiving regular antihypertensive treatment. The presence of
dyslipidaemia was defined as having high triglyceride (fasting
triglycerides $1.69 mmol/L), low HDL-C (fasting HDL-C
,1.29 mmol/L in women and ,1.04 mmol/L in men), high
LDL-C (fasting LDL-C $3.4 mmol/L) [18] or taking lipid
lowering agents. Insulin resistance was estimated using the
homeostasis model assessment index of insulin resistance
(HOMA-IR), calculated by the formula (FG in mmol/L6 fasting
insulin in mIU/L /22.5) [19].
Biochemical Assessments
Serum levels of the biomarkers were measured from stored
serum samples collected at CRISPS2 (baseline of this study).
Serum A-FABP [13], IL-6 and TNF-a R2 were measured with
commercial ELISA kits (BioVendor – Laboratory Medicine,
Modrice, Czech Republic for A-FABP; Bender MedSystems
GmbH, Vienna, Austria for IL-6; R&D Systems, Inc., Minneap-
olis, USA for TNF-a R2). hsCRP and total adiponectin levels were
measured using in-house sandwich ELISA assays established in
our laboratory as described previously [14].
Statistical Analyses
All statistical analyses were performed with SPSS Statistics 19
(SPSS, Chicago, IL). Results are presented as means 6 SD or
medians (interquartile range, IQR) as appropriate. Data that were
not normally distributed, as determined using Kolmogorox-
Smirnov test, were natural-logarithmically transformed to obtain
near normality before analysis. A-FABP, IL-6, TNF-a R2 and
adiponectin levels showed gender-specific dimorphisms and were
sex-adjusted. Differences in baseline characteristics with subse-
quent glycaemia status were compared using x2 tests for
categorical variables and one-way ANOVA for continuous
variables. The level of each biomarker was divided into high
and low categories by an optimal cutoff derived from Youden
Index (sensitivity + specificity 21) [20]. Multiple logistic regression
was applied to estimate the odds ratio (OR) and 95% confidence
interval (CI) of each biomarker by comparison of the two
categories for incident diabetes. We used the low level as the
reference for TNF-a R2, IL-6, hsCRP and A-FABP; and the high
level as reference for adiponectin. In multivariate analyses, we
adjusted for clinical parameters and conventional risk factors
including age, sex, family history of diabetes in first degree
relatives, smoking status, physical activity, hypertension, waist
circumference (WC), fasting glucose (FG) and dyslipidaemia. Log-
likelihood ratio test was used to compare the likelihood of incident
diabetes before and after addition of one, followed by multiple,
biomarker levels to the clinical diabetes prediction model (CDP),
which included the aforementioned clinical parameters and
diabetes risk factors. A biomarker risk score was counted by the
number of biomarkers predictive of diabetes. Receiver Operating
Characteristic (ROC) curves were used to assess the performance
of different methods for diabetes risk prediction. The area under
ROC curves (AUC) were compared with a nonparametric
approach as described by DeLong et al [21]. Sensitivities,
specificities, and positive and negative predictive values for the
different prediction models were determined. Two-sided p-values
less than 0.05 were considered statistically significant.
Results
Seventy-six of 1300 subjects (5.85%) had developed type 2
diabetes when reassessed after a median interval of 5.3 (inter-
quartile range: 4.59–5.80) years. Table 1 shows that at baseline,
compared to those without incident diabetes at follow-up, subjects
with incident diabetes were significantly older, more obese, had
greater BMI and WC, higher FG, 2 h-glucose, insulin, HOMA-
IR, triglyceride and LDL-C, but lower level of HDL-C. They were
more likely to have hypertension, dyslipidaemia, IGT or impaired
fasting glucose (IFG) [17]. For the serum biomarkers, subjects with
incident diabetes had lower levels of adiponectin (P= 0.001), but
higher levels of hsCRP (P,0.001), IL-6 (P= 0.014), TNF-a R2
(P,0.001) and A-FABP (P,0.001).
The levels of biomarkers were divided into low and high
categories by their respective optimal cutoffs, i.e. 5.94 ug/ml (M)
and 6.03 ug/ml (F) for adiponectin; 2.13 ng/ml (M) and 2.05 ng/
ml (F) for TNF-a R2; 21.72 ng/ml (M) and 26.33 ng/ml (F) for A-
FABP; 0.71 pg/ml (M) and 0.34 pg/ml (F) for IL-6, and 0.62 mg/
L for hsCRP. Each of the five serum biomarkers was tested
individually by multivariate analysis to examine for its indepen-
dent association with incident diabetes, with adjustments made for
age, sex, family history of diabetes, smoking status, physical
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activity, hypertension, WC, FG and dyslipidaemia. All five
biomarkers were, individually, significantly associated with inci-
dent diabetes. The ORs for hypoadiponectinaemia, TNF-a R2, A-
FABP, IL-6 and hsCRP were 2.62 (P= 0.001), 2.19 (P = 0.004),
2.26 (P= 0.005), 2.25 (P = 0.009) and 2.26 (P= 0.010) respectively.
Table 1. Baseline clinical and biochemical characteristics of subjects with and without incident type 2 DM in 5.3 years.
Baseline parameters DM Non-DM p-value
N 76 1224 –
Age (year) 56.6610.5 49.8610.9 ,0.001
Female (%) 50.0 55.2 0.375
Current/Former smoker (%) 31.6 23.9 0.131
Physical activity (%)a 26.0 30.8 0.388
Family history of diabetes 21.1 16.7 0.329
Central Obesity (%) 46.1 23.8 ,0.001
Waist circumference (cm) – – ,0.001b
Male 89.069.02 82.868.46 –
Female 81.568.91 74.968.67 –
Body Mass Index (kg/m2) 25.863.5 23.763.3 ,0.001
Hypertension (%) 35.5 20.6 0.002
Systolic blood pressure (mmHg) – – ,0.001c
With hypertensive treatment 140.1625.9 136.0616.8 –
Without hypertensive treatment 126.7617.4 118.5617.0 –
Diastolic blood pressure (mmHg) – – 0.001c
With hypertensive treatment 88.1610.1 82.3610.3 –
Without hypertensive treatment 78.068.35 74.0610.2 –
IGT/IFG (%) 71.1 24.1 ,0.001
Fasting glucose (mmol/L) 5.460.6 5.060.5 ,0.001
2-hour glucose (mmol/L) 8.461.6 6.561.7 ,0.001
Fasting insulin (mIU/L)d 8.75(6.63–15.0) 6.95(5.08–9.80) ,0.001
HOMA-IRd 2.16(1.49–3.54) 1.53(1.11–2.24) ,0.001
Dyslipidaemia (%) 77.3 60.0 0.003
Total cholesterol (mmol/L)e 5.4861.09 5.2560.87 0.032
LDL cholesterol (mmol/L)e 3.4560.97 3.2560.77 0.036
HDL cholesterol (mmol/L)e 1.3260.33 1.4360.38 0.014
Triglycerides (mmol/L)de 1.3(0.9–2.0) 1.1(0.8–1.5) ,0.001
Adiponectin (ug/ml)d – – 0.001b
Male 4.53(3.07–5.93) 5.88(3.78–9.19) –
Female 6.73(4.18–9.47) 8.20(5.74–11.8) –
TNF-alpha R2 (ng/ml)d – – ,0.001b
Male 2.24(1.89–2.64) 1.96(1.69–2.31) –
Female 2.06(1.56–2.53) 1.76(1.52–2.07) –
hsCRP (mg/L)d 1.24(0.65–2.12) 0.64(0.30–1.39) ,0.001
Interlukin-6 (pg/ml)d – – 0.014b
Male 0.84(0.48–1.26) 0.58(0.36–0.86) –
Female 0.59(0.37–0.88) 0.51(0.35–0.75) –
A-FABP (ng/ml)d – – ,0.001b
Male 26.36(16.58–36.69) 18.05(13.28–24.00) –
Female 31.16(23.8–36.93) 22.03(16.29–30.20) –
Mean 6 SD, median (interquartile-range), or percentage as appropriate.
aPhysical activity: active if having moderate intensity exercise for at least 30 minutes in one month. bSex-adjusted; cAdjusted for hypertensive treatment; dLog
transformed before analysis. eExcluded subjects on lipid treatment;
Central obesity: waist circumference $90 cm (M)/80 cm (F).
Hypertension: systolic blood pressure $140 mmHg, diastolic blood pressure $90 mmHg, or on hypertensive treatment.
Dyslipidaemia: triglycerides $1.7 mmol/L, HDL cholesterol ,1.0 mmol/L (M)/1.3 mmol/L (F), LDL cholesterol $3.4 mmol/L, or on lipid treatment.
doi:10.1371/journal.pone.0036868.t001
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We constructed a clinical diabetes prediction model (CDP)
using patients’ baseline demographic parameters and conventional
risk factors (age, sex, WC, FG, smoking status, physical activities,
family history of diabetes, presence of hypertension and dyslipi-
daemia). Effect of the addition of biomarkers to the CDP model
was shown in Table 2. The largest increment in the log-likelihood
of the model was observed after the addition of adiponectin.
Addition of each of the other biomarkers to this ‘‘CDP +
adiponectin’’ model resulted in further significant increase in log-
likelihood (Table 2). Performance of the prediction models was
examined by ROC curves analysis. Table 3 showed the
comparison of the AUCs of different ‘‘CDP + biomarker(s)’’
models with the baseline CDP model and also the ‘‘CDP + 2 h-
glucose’’ model. Adiponectin together with TNF-a R2, when
added to the CDP, generated a model with an AUC of 0.830 (95%
CI: 0.808–0.850), which was significantly better than the baseline
CDP (AUC=0.802, P= 0.0306) and was comparable to the
‘‘CDP + 2 h-glucose’’ model (AUC=0.852 [95% CI: 0.831–
0.870], P= 0.2954) (Fig. 1) (Table 3). This combination required
the smallest number of biomarkers to achieve a performance
comparable to 2 h-glucose. Adding fasting insulin level, a marker
of insulin resistance, to the CDP did not show significant AUC
improvement (AUC=0.803 [95% CI: 0.780–0.824], P= 0.65). A
biomarker risk score, counted by the number of biomarkers
predictive of diabetes, i.e. low adiponectin and/or high TNF-a
R2, was analyzed by multiple logistic regression as shown in
Table 4. The ORs were 2.802 (P= 0.006) and 5.862 (P,0.001) for
a score of 1 and 2 respectively. The AUC of the ‘‘CDP +
biomarker risk score’’ model was 0.829 (95% CI: 0.808–0.849)
which was similar to the ‘‘CDP + adiponectin + TNF-a R2’’
model. The sensitivity and specificity for diabetes prediction of the
‘‘CDP + biomarker risk score’’ model were 70.7% and 83.3%
respectively. This model increased the positive predictive value
from 21.5% to 31.3% without jeopardizing the negative predictive
value (96.4% vs. 97.3%) when compared with the baseline CDP
model (Table 5).
Discussion
Various serum biomarkers representing the process of adipokine
dysregulation and adipose tissue inflammation have been shown to
be associated with the development of obesity-related type 2
diabetes. To look for the best predictive obesity-related biomarkers
for type 2 diabetes in this 5-year prospective study among
Southern Chinese, we focused on biomarkers which were
previously shown to be associated with incident diabetes or
worsening of glycaemic status in Chinese subjects. Adiponectin
[14], A-FABP [13] and hsCRP [8] were therefore selected. IL-6
and TNF-a R2 were also included, being adipokines upstream of
CRP in the inflammatory cascades. Individually, low adiponectin,
high A-FABP, TNF-a R2 (a surrogate marker of TNF-a), IL-6 or
hsCRP at baseline was independently predictive of 5-year diabetes
risk in this cohort, after adjustment for nine conventional risk
factors, including age, sex, family history of diabetes, smoking,
physical inactivity, hypertension, waist circumference, fasting
glucose and dyslipidaemia. Each of these biomarkers could
increase the likelihood of diabetes development when added to a
clinical prediction model comprising these conventional risk
factors, with the increase being greatest following the addition of
adiponectin. Based on ROC analysis, the combined use of serum
adiponectin and TNF-a R2 resulted in a significant enhancement
of diabetes prediction by this clinical prediction model, with the
enhancement being comparable to that provided by 2-hour
plasma glucose, as assessed with a 75 g OGTT.
The association of IL-6 with insulin resistance was suggested by
the observation in animal studies that passive immunoneutralisa-
tion of IL-6 led to an improved insulin sensitivity in insulin
resistant mice with transgenic NFkB activation [22]. Accordingly,
elevated levels of IL-6 also predicted an increased risk of diabetes
in postmenopausal women [9] and in the current study. On the
contrary, however, blocking the action of IL-6 in rheumatoid
arthritis patients led to enhanced plasma glucose levels [23], and
IL-6 infusion acutely increased insulin-stimulated glucose disposal
in humans, probably via AMP-activated protein kinase in skeletal
muscles [24]. The role of IL-6 in insulin resistance in humans thus
remains to be resolved. It has also been suggested that, as TNF-a
can trigger IL-6 release, increased systemic IL-6 levels may reflect
enhanced adipose tissue production of TNF-a, the actual driver
behind obesity-related insulin resistance [23]. High hsCRP was
also shown to be associated with an increased diabetes risk, when
analyzed individually, in some previous studies. [8,25,26,27]
However, heterogeneity existed as was documented by a recent
meta-analysis of 16 published studies [27], with the authors
concluding that CRP may not be an independent risk factor for
Table 2. Log-likelihood ratio tests comparing the change before and after addition of biomarkers.
Level Model Referent model -2LL Change in -2LL p-value
0 CDP – 486.254 – –
1 CDP + Adiponectin CDP 474.104 12.15 0.0005
CDP + TNF-a R2 477.709 8.545 0.0035
CDP + A-FABP 478.265 7.989 0.0047
CDP + IL-6 478.988 7.266 0.0070
CDP + hsCRP 478.938 7.316 0.0068
2 CDP + Adiponectin + A-FABP CDP + Adiponectin 465.421 8.683 0.0032
CDP + Adiponectin + TNF-a R2 466.023 8.081 0.0045
CDP + Adiponectin + IL-6 467.771 6.333 0.0119
CDP + Adiponectin + hsCRP 468.742 5.362 0.0206
-2LL, -2log-likelihood; p-value (x2, df = 1);
All biomarker levels were sex specific (except for hsCRP).
CDP: Sex, Age, Waist circumference, fasting glucose, hypertension, dyslipidaemia, family history of diabetes, physical activity and smoking status.
TNF-a R2: tumor neurosis factor-alpha receptor 2; hsCRP, high sensitivity C-reactive protein; IL-6, Interleukin-6; A-FABP, adipocyte-fatty acid-binding protein.
doi:10.1371/journal.pone.0036868.t002
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type 2 diabetes, as it is a downstream marker of the inflammatory
process, stimulated by pro-inflammatory cytokines including IL-6
and TNF-a, the secretion of which are reciprocally regulated by
adiponectin [28]. In the current study, hsCRP and IL-6 were not
as useful as TNF-a R2, when used in addition to adiponectin for
the prediction of diabetes risk. Similarly, serum A-FABP levels,
shown to be associated with various cardiometabolic risk factors in
Chinese [13] and Caucasians [29], and independently predictive
Table 3. Comparisons of AUCs of different diabetes prediction models.
Level Model AUC (95% CI) P-value (Referent: CDP)
P-value (Referent: 2 h-
glucose)
0 CDP 0.802 (0.779–0.823) Referent –
1 CDP + 2 h-glucose 0.852 (0.831–0.870) 0.0078 Referent
CDP + Fasting insulin 0.803 (0.780–0.824) 0.6512 0.0094
CDP + Adiponectin 0.816 (0.794–0.837) 0.1375 0.0621
CDP + TNF-a R2 0.814 (0.792–0.835) 0.1982 0.0723
CDP + A-FABP 0.809 (0.787–0.830) 0.4304 0.0308
CDP + hsCRP 0.812 (0.790–0.833) 0.2778 0.0347
CDP + IL-6 0.807 (0.785–0.829) 0.4992 0.0231
2 CDP + Adiponectin + TNF-a R2 0.830 (0.808–0.850) 0.0306 0.2954
CDP + Adiponectin + A-FABP 0.825 (0.804–0.846) 0.0633 0.1820
CDP + Adiponectin + IL-6 0.824 (0.802–0.844) 0.0691 0.1606
CDP + Adiponectin + hsCRP 0.824 (0.802–0.844) 0.0938 0.1618
AUC, Area under the curve; All biomarker levels were sex-specific except for hsCRP;
CDP: Sex, Age, Waist circumference, fasting glucose, hypertension, dyslipidaemia, family history of diabetes, physical activity and smoking status.
TNF-a R2: tumor neurosis factor-alpha receptor 2; hsCRP, high sensitivity C-reactive protein; IL-6, Interleukin-6; A-FABP, adipocyte-fatty acid-binding protein.
doi:10.1371/journal.pone.0036868.t003
Figure 1. ROC curves for different diabetes prediction models. CDP, clinical diabetes prediction model.
doi:10.1371/journal.pone.0036868.g001
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of diabetes in a CRISPS subcohort [13], appeared to be less useful
than TNF-a R2, when used in conjunction with adiponectin, in
predicting diabetes development in this larger cohort. The
mechanisms underlying the dysglycaemic effect of A-FABP are
not fully understood although animal studies suggest several
potential mechanisms [28]. In mice, genetic deficiency of A-FABP
is associated with enhanced insulin signaling, in part via a
reduction of TNF-a, IL-6 and other pro-inflammatory cytokines
[28].
TNF-a R2 and adiponectin emerged as the better combination
of biomarkers in our diabetes prediction models. TNF-a has been
considered as a key mediator of obesity-related insulin resistance
because of its increased expression in obesity and its inhibitory
effect on insulin receptor signaling [30]. While earlier reports
failed to demonstrate the association of serum TNF-a level with
diabetes development [10,12], a more recent study demonstrated
that raised serum TNF-a R2 levels, measured as a surrogate
marker for TNF-a because of its superior sensitivity and reliability
when assayed in frozen plasma, were associated with a modest
increase in diabetes risk [9]. Adiponectin, on the other hand, is an
adipokine with insulin-sensitizing, anti-inflammatory and vasopro-
tective properties which has been extensively studied and reviewed
in the past decade [28,31]. Since the first report of its role in
diabetes development in a case-control study of Pima Indians [32],
an association between low adiponectin and the risk of diabetes
has been consistently reported across diverse populations
[11,12,26,33,34,35]. Adiponectin has also been selected for
construction of diabetes prediction models in previous studies
[26,36]. In a German study [26], adiponectin modestly increased
the ROC AUC by 0.011 to 0.831 when added to a basic model
which included already the inflammatory markers CRP, IL-6,
soluble ICAM-1 and soluble E-selectin levels on top of
demographic and lifestyle factors, family history of diabetes, blood
pressure, lipid levels. In the Inter99 cohort, adiponectin, together
with CRP, ferritin, IL-2 receptor A, fasting glucose and insulin,
performed similarly as 2-hour plasma glucose (OGTT) or 2-hour
insulin in ROC AUC analysis. In this study we demonstrated that
only two obesity-related biomarkers, namely adiponectin and
TNF-a R2, were required to achieve an effect comparable to 2-
hour glucose, when added to a predictive model consisting of non-
invasively assessable clinical parameters together with fasting
glucose and lipid levels.
Different diabetes prediction models have been published
previously. They could be derived from clinical parameters [37],
serum biomarkers [36], or a combination of both [38]. The 2-hour
post-OGTT plasma glucose has been shown to be the strongest
single predictor for diabetes development in Southern Chinese
[39]. Although the 2-hour glucose, when used alone, was shown to
be inferior to a model derived from readily available clinical
variables in the San Antonio Study (77.5% vs. 84.3%) [40], or
Table 4. Multivariate prediction of diabetes according to CDP and biomarker risk score.
OR (95%CI) p-value
Men 0.507 (0.272–0.947) 0.033
Age 1.042 (1.016–1.068) 0.001
WC 1.044 (1.013–1.076) 0.005
FG 3.389 (2.025–5.672) ,0.001
HT 0.757 (0.421–1.360) 0.352
Dyslipidaemia 1.198 (0.657–2.185) 0.556
Family history of DM 1.661 (0.885–3.118) 0.114
Physical activity 0.637 (0.356–1.141) 0.129
Smoking status 1.226 (0.646–2.332) 0.534
Biomarker risk score ,0.001
0= high adiponectin and low TNF-a R2 Referent –
1= either low adiponectin or high TNF-a R2 2.802 (1.337–5.873) 0.006
2= low adiponectin and high TNF-a R2 5.862 (2.601–13.212) ,0.001
WC, waist circumference; FG, fasting glucose; HT, hypertension; TNF-a R2: tumor neurosis factor-alpha receptor 2.
doi:10.1371/journal.pone.0036868.t004
Table 5. Performance of different models on diabetes risk prediction.
Model Accuracy (%) Sensitivity (%) Specificity (%)
Positive
predictive
value (%)
Negative
predictive
value (%)
CDP 68.4 82.7 67.5 21.5 97.3
CDP + 2 h-Glucose 67.6 90.7 66.2 22.4 98.5
CDP + Biomarker risk score 82.6 70.7 83.3 31.3 96.4
CDP: sex, age, waist circumference, fasting glucose, hypertension, dyslipidaemia, family history of diabetes, physical activity and smoking status.
Biomarker risk score: (as described in table 4).
Prevalence rate 9.7% [1].
doi:10.1371/journal.pone.0036868.t005
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equivalent to a diabetes prediction score involving six biomarkers
[36] in the Inter99 cohort, it is noteworthy that the 2-hour glucose
did further improve diabetes prediction based on clinical variables
in the San Antonio Study [40], and even more so in the current
study. Nonetheless, the OGTT is notorious for being inconve-
nient, cumbersome and associated with large intra-individual
variation in glucose responses. In our pursuit of a potential
alternative to 2-hour glucose we aimed at identifying biomarkers
comparable to 2-hour glucose in improving the performance of
our clinical diabetes prediction model. Fasting insulin, a marker of
insulin resistance, was tested but did not result in significant
improvement in diabetes risk prediction. In the process of model
development, we categorized the biomarkers to low and high
levels, with reference to mathematically derived optimal cut-offs,
and formulated a simple biomarker risk score by counting the
number of biomarkers predictive of diabetes development. As only
two biomarkers were needed in our model, the biomarker risk
score was simply 0, 1 or 2. This biomarker risk score was also
shown to be an independent predictor of diabetes risk in our
cohort and improved the performance of the clinical prediction
model to a similar level as the addition of 2-hour glucose.
As our study is limited by the relatively small number of subjects
with incident diabetes, we have not performed model validation in
the current report. In addition, laboratory measurements for
adiponectin and TNF-a R2 are still not readily available in clinical
practice. However, our postulated diabetes prediction model
involved only simple anthropometric measurements and a single
fasting blood sample for identifying patients at increased risk of
developing type 2 diabetes, which would be more convenient than
the conventional oral glucose tolerance test. In summary, our data
highlight the potential combined use of serum adiponectin and
TNF-a R2 for diabetes prediction model construction in the
Chinese population, as an attractive alternative to existing
methods which warrant further validation in other populations.
Identifying individuals at risk using simple and convenient
prediction tools, followed by the commencement of strategic
preventive measures, should be a useful approach to halt the
epidemic of type 2 diabetes.
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